Abstract #0898
Improved Behavioural Recovery Correlated with MRI and Morphology After SDZ EAA494 Treatment, A Novel NMDA Receptor Antagonist, Evaluated in Experimental Stroke Treatment
Z. Chen, A. Sauter and B. Bjelke, Karolinska Institutet, Stockholm, Sweden and Novartis Pharma, Basel, Switzerland.
